Diverse in our backgrounds, training, and thinking
United in our mission

Tim is an Associate Professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering at MIT. Tim graduated with his SB and MEng from MIT, and his MD/PhD from the Harvard-MIT Health Sciences and Technology program. He is a core member of the MIT Synthetic Biology Center and a co-founder of multiple biotechnology companies innovating new diagnostic and therapeutic technologies for human health, including Sample6, Senti Biosciences, Synlogic, Eligo Biosciences, BiomX, and Engine Biosciences.  He currently serves as CEO of Senti Biosciences.

Tim’s research at MIT focuses on engineering platforms for computing and memory in living cells and applying these to create adaptive medicines as next-generation cell and gene therapies for important human diseases. His work also includes developing novel technology platforms to interrogate and correct diseased cell states. He is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, among others.

Dr. Gupta works closely with, and mentors, world-class scientists and entrepreneurs to build companies to develop innovative products and platforms that address critical healthcare needs. Dr. Gupta and his team support company creation, equity and IP portfolio management, preclinical and clinical development of breakthrough technologies, business development, licensing & industry alliances including pilot programs and co-development partnerships with startups and major industry players. Dr. Gupta’s leadership has led to multiple successful partnerships with industry, and he has directly played an instrumental role in company co-creation of several Cedars-Sinai spinoffs notably Prometheus Biosciences, Gemelli Biotech, and Gravidas Diagnostics.

Dr. Gupta was a nominated member of the Business Advisory Council of the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP) and has served as member of their Innovation and Competitiveness Task Force. He holds a bachelor’s and doctorate degrees in pharmaceutical sciences.

Before beginning her investing career, Joy was a lung cancer program manager at Genome Institute of Singapore and prior to that, she was a researcher at Prof Sydney Brenner’s Molecular Engineering Lab. She also did a stint in biopharma manufacturing at Genentech in North America.

She graduated with a DPhil in Clinical Medicine, and Saïd Business School’s Finance Lab from University of Oxford. She received her Bachelor’s degree in Material Science and Engineering from Nanyang Technological University.

Previously, José was chief medical officer at Biothera where he was responsible for the clinical development program of Imprime-PGG. Prior to that, he was the chief medical officer for Bionomics where he was responsible for the clinical development of its oncology pipeline, including antivascular agents, monoclonal antibodies and small molecule kinase inhibitors. Before that, he served as vice president, clinical development, at Celgene Corporation, where he was responsible for the Phase III development of Abraxane in pancreatic cancer, lung cancer and metastatic breast cancer.

José is author or co-author of more than 60 publications in the area of Oncology, with over 6,000 citations. He received his M.D. in oncology and cancer biology from the Universidad de Montevideo, Uruguay.